• English
    • français
  • Help
  •  | 
  • Contact
  •  | 
  • About
  •  | 
  • Login
  • HAL portal
  •  | 
  • Pages Pro
  • EN
  •  / 
  • FR
View Item 
  •   LillOA Home
  • Liste des unités
  • Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192
  • View Item
  •   LillOA Home
  • Liste des unités
  • Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

A bioactive coating enhances bone allografts ...
  • BibTeX
  • CSV
  • Excel
  • RIS

Document type :
Article dans une revue scientifique: Article original
DOI :
10.1002/jor.24409
PMID :
31283054
Permalink :
http://hdl.handle.net/20.500.12210/75120
Title :
A bioactive coating enhances bone allografts in rat models of bone formation and critical defect repair
Author(s) :
Cheng, Tegan L. [Auteur]
Leblanc, Elisabeth [Auteur]
Kalinina, Anastassia [Auteur]
Cantrill, Laurence C. [Auteur]
Valtchev, Peter [Auteur]
Dehghani, Fariba [Auteur]
Little, David G. [Auteur]
Schindeler, Aaron [Auteur]
Journal title :
Journal of orthopaedic research . official publication of the Orthopaedic Research Society
Abbreviated title :
J. Orthop. Res.
Publication date :
2019-07-08
ISSN :
1554-527X
Keyword(s) :
critical defect
PDIB
BMP-2
allograft
bone graft
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
Bone allografts are inferior to autografts for the repair of critical-sized defects. Prior studies have suggested that bone morphogenetic protein-2 (BMP-2) can be combined with allografts to produce superior healing. We ...
Show more >
Bone allografts are inferior to autografts for the repair of critical-sized defects. Prior studies have suggested that bone morphogenetic protein-2 (BMP-2) can be combined with allografts to produce superior healing. We created a bioactive coating on bone allografts using polycondensed deoxyribose isobutyrate ester (PDIB) polymer to deliver BMP-2 +/- the bisphosphonate zoledronic acid (ZA) and tested its ability to enhance the functional utility of allografts in preclinical Wistar rat models. One ex vivo and two in vivo proof-of-concept studies were performed. First, PDIB was shown to be able to coat bone grafts (BGs). Second, PDIB was used to coat structural allogenic corticocancellous BG with BMP-2 +/- ZA +/- hydroxyapatite (HA) microparticles and compared with PDIB-coated grafts in a rat muscle pouch model. Next, a rat critical defect model was performed with treatment groups including (i) empty defect, (ii) BG, (iii) collagen sponge + BMP-2, (iv) BG + PDIB/BMP-2, and (v) BG + PDIB/BMP-2/ZA. Key outcome measures included detection of fluorescent bone labels, microcomputed tomography (CT) quantification of bone, and radiographic healing. In the muscle pouch study, BMP-2 did not increase net bone volume measured by microCT, however, fluorescent labeling showed large amounts of new bone. Addition of ZA increased BV by sevenfold (p < 0.01). In the critical defect model, allografts were insufficient to promote reliable union, however, union was achieved in collagen/BMP-2 and all BG/BMP-2 groups. Statement of clinical significance: These data support the concept that PDIB is a viable delivery method for BMP-2 and ZA delivery to enhance the bone forming potential of allografts. (c) 2019 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 37:2278-2286, 2019.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
INSERM
Université de Lille
Collections :
  • Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192
Submission date :
2022-06-15T13:59:03Z
Université de Lille

Mentions légales
Université de Lille © 2017